Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  24.80 1.8% 1,405.00 6,483,102 16:35:03
Bid Price Offer Price High Price Low Price Open Price
1,406.20 1,407.00 1,416.00 1,385.40 1,390.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.00 6,221.00 93.90 15.0 70,671
Last Trade Time Trade Type Trade Size Trade Price Currency
17:47:45 O 445 1,388.353 GBX

Glaxosmithkline (GSK) Latest News

More Glaxosmithkline News
Glaxosmithkline Investors    Glaxosmithkline Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BMO UK HIGH INCOME TRUST PLC 5.44% 2020-12-31

Glaxosmithkline (GSK) Discussions and Chat

Glaxosmithkline (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-25 18:29:011,388.354456,178.17O
2021-01-25 18:29:001,390.392092,905.92O
2021-01-25 18:29:001,393.251,48320,661.88O
2021-01-25 18:29:001,391.121512,100.59O
2021-01-25 17:47:451,403.275,09471,482.42O
View all Glaxosmithkline trades in real-time

Glaxosmithkline (GSK) Top Chat Posts

Glaxosmithkline Daily Update: Glaxosmithkline Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Glaxosmithkline was 1,380.20p.
Glaxosmithkline Plc has a 4 week average price of 1,336.60p and a 12 week average price of 1,294p.
The 1 year high share price is 1,847p while the 1 year low share price is currently 1,284p.
There are currently 5,029,983,667 shares in issue and the average daily traded volume is 8,564,581 shares. The market capitalisation of Glaxosmithkline Plc is £70,671,270,521.35.
spoole5: Unfortunately gsk price never reacts to good news!
montedawnster: You are not all wrong Porsche boy, but your US stock is going to take a hit with rising dollar. Doubt we'll see a dividend drop on GSK anytime soon and share price has good recovery potential from many angles.
montyhedge: GSK Biopharma 20p and growing dividend, GSK Healthcare 60p dividend safe but boring. I still reckon special dividend on the split. This is going to be the best thing ever.GSK Healthcare is safe and boring, holding back GSK Biopharma, that's the way I see it.
montyhedge: Won't be long for Vir and GSK vaccine being tested now.GSK bought $250m 6% stake, look at VIR shareprice GSK have a winner in shares anyway, lol.
montyhedge: ICI split Zeneca at 600p then they merged with Swedish Astra, become Astra Zeneca 600p to what 8600p that's what can happen.GSK have seen what can happen, some argue the boring safe healthcare holding back the shareprice.Can't wait it's going to be good GSK Biopharma and the safe boring GSK Healthcare.
tradermichael: Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection Trial targeted to begin in 1Q:2021 at multiple sites across the UK SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection. The AGILE trial platform, which will be the first to test VIR-7832 in humans, uses adaptable protocols and statistical models to enable the evaluation of candidate medicines for COVID-19 treatment. The initiative is a collaboration between the University of Liverpool, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, University of Southampton and Lancaster University and coordinated by the National Institute for Health Research Southampton Clinical Trials Unit across the UK Clinical Research Facility Network. The trial is due to begin in the first quarter of 2021. George Scangos, Ph.D., chief executive officer of Vir, said: “We are pleased to have the support of the NHS behind our efforts to evaluate and advance VIR-7832 for the treatment and potential prevention of COVID-19. This study will be critical to our efforts as we work to understand whether the modifications we have made to this monoclonal antibody increase its potency and stimulate a T cell response to not only provide therapeutic benefits but also potentially confer a vaccine-like effect that could be applicable to prophylaxis.” Dr. Hal Barron, chief scientific officer and president R&D, GSK, said: “While vaccine development has been very successful, current infection and hospitalization rates show that multiple vaccines and therapeutic options will be needed to combat and ultimately end this pandemic. We are grateful to everyone involved in the AGILE study for supporting this important research and expect initial results from the study to provide important insights into the use of VIR-7832 early in the course of infection with SARS-CoV-2.” VIR-7832 is set to become the second monoclonal antibody from the Vir-GSK collaboration to be investigated as a potential COVID-19 treatment. The first antibody, VIR-7831, is currently being investigated in two global phase 3 studies; for the early treatment of COVID-19 in patients who are at high risk of hospitalization, and for the treatment of hospitalized patients with COVID-19. Phase 1b/2a AGILE Study Design AGILE is a randomized, controlled, multi-center, seamless, adaptive Phase 1b/2a platform for the rapid evaluation of candidates of COVID-19 treatment in hospitalized patients and also in the community with early disease. The AGILE platform will assess VIR-7832 and VIR-7831 in adult outpatients with mild to moderate COVID-19 infection. The dose-escalation Phase 1b part of the study will evaluate the safety and tolerability of a single dose of VIR-7832 given by intravenous (IV) infusion and determine the dose for evaluation in the Phase 2a part of the study. A total of 24 study participants will be randomized 3:1 to VIR-7832 or placebo. The Phase 2 part of the study will include three treatment arms: 50 patients randomized to VIR-7832, 50 patients to VIR-7831, and 25 patients to placebo. The co-primary endpoints are safety and virologic activity of VIR-7832 as assessed by a change in SARS-CoV-2 viral load from baseline to Day 8. The Phase 2 part of the study also will assess the T cell responses to SARS-CoV-2 of VIR-7832 and VIR-7831. The trial is being conducted at up to five sites in the UK.
essentialinvestor: AZN my smallest holding so would not say I like it so much. Astra should have at least 4 years of strong earnings growth ahead, the bearish case is that's already in the price. GSK is the out of favour play, coupled with potential value creation from the consumer healthcare split. GSK share price progress (longer term) also depends on progress in their oncology pipeline.
daneswooddynamo: Thanks for the advice Polaris I will do my best. My point was that it is old news. In terms of the impact on vectura which is a lot more meaningful than gsk I see that the share price had a slightly more meaningful response in November
polaris: Yes, with the share price erosion here over the last 12 months, who is going to notice another small cut from cash balance? GSK respiratory division now mostly Ellipta series. Not as if anyone is working towards generics there...
geckotheglorious: Plenty of news GSK side today GlaxoSmithKline's Benlysta wins FDA approval for lupus nephritis The FDA has approved GlaxoSmithKline's (GSK +0.8%) intravenous and subcutaneous Benlysta for Lupus nephritis (LN), making it the first therapy ever approved for the indication. LN is severe form of systemic lupus erythematosus that can cause late-stage renal failure and require dialysis or kidney replacement in the worst cases. hTTps:// Surface Oncology shares rise 7% on licensing deal with GSK for immunotherapy program Surface Oncology (NASDAQ:SURF) inks an agreement with GlaxoSmithKline (NYSE:GSK) for worldwide development and commercial rights to its preclinical program SRF813. Under the terms of the agreement, Surface Oncology will receive an upfront payment of $85M, potential milestone payments of $730M, as well as be eligible to receive tiered royalties on global net sales. hTTps:// DZ cuts FV to 1700p!
Glaxosmithkline share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210126 02:35:20